


Heterogeneity in Critical Illness: Challenges and Opportunities

Kathryn A. Hibbert, MD

24 July, 2022

47 year old healthy man presents with subjective fever, muscle aches and vague abdominal pain.






Outline

- Context and Definitions
- Syndromes versus Diseases
- Impact of Heterogeneity
- Network Physiology Opportunities


Burden of Critical Illness – Annual Incidence (United States)

“Acute Respiratory Distress Syndrome”



Pre-COVID-19

~30% Mortality



15-60% Mortality

Significant morbidity, mortality, and health care burden associated with these conditions


Acute Respiratory Distress Syndrome


The Berlin Definition

The ARDS Definition Task Force*

Table 3. The Berlin Definition of Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome	
Acute	Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Abn'l Imaging	Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules
Not Something Else	Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
Low Oxygen Levels	$200 \text{ mm Hg} < \text{Pao}_2/\text{Fio}_2 \leq 300 \text{ mm Hg}$ with PEEP or CPAP $\geq 5 \text{ cm H}_2\text{O}^c$ $100 \text{ mm Hg} < \text{Pao}_2/\text{Fio}_2 \leq 200 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$ $\text{Pao}_2/\text{Fio}_2 \leq 100 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$







Pathologic features

- Loss of endothelial integrity
- Alveolar flooding and hyaline membrane formation
- Later fibrosis with maladaptive injury repair


Definition of Sepsis




“Life-threatening organ dysfunction caused by a dysregulated host response to infection”



Critical Illness as Final Common Pathway





Critical Illness as Final Common Pathway




Sepsis and ARDS are Syndromes, not Diseases

- No specific biomarker (e.g. a blood test) to identify either sepsis or ARDS
- Diagnosis can be made at the bedside, but may not be specific (or even that sensitive)
- Purposefully inclusive definitions based on easily accessible clinical information
- Developed from need for a case definition for research and early intervention


- No pulmonary lesion
- Other diagnostic
- Pneumonia
- Diffuse alveolar damage






Have we really come that far?

Early Identification → Early Intervention




Timing of antibiotics in septic shock affects survival



Ventilator management at ARDS onset impacts survival


A Challenge of Syndromic Definitions: Heterogeneity!!



- **Subphenotypes:** groups that appear different in some way
- **Endotypes:** groups with distinct disease processes


How to Identify Subgroups in ARDS

- What caused it?
 - Direct versus indirect injury
- What does it look like? (anatomic)
 - Focal versus diffuse
- What does it look like? (biomarker profile)
 - Latent class analysis




Sepsis Phenotypes

A All phenotypes combined





A Ratio of IL-6 to a phenotype




How do we know our subgroups are real?

E PROWESS trial (n=1690) (drotrecogin alfa vs placebo)







Some subgroups are identifiable




Some subgroups are
not identifiable







*And it's probably even
worse than we
know....*

Why Does Heterogeneity Matter?



Variable outcomes
and response to
therapy






Accurate Prognosis
&
Personalized and
Effective Therapy

Nitric Oxide
Surfactant/perflourocarbon
Prostaglandin E1
Lysophyline
Ibuprofen
Procysteine
Anticryptokine/antiendotoxin
Ketoconazole
Streptokinase
Neutrophil elastase inhibitor
sPLA2 inhibitor
rhAPC
Albuterol/salmeterol
Furosemide
Cisatracurium
GMCSF
Beta Agonists
Statins

Alkaline Phosphatase
Granulocyte Colony-stimulating Factor
Anti-tumor Necrosis Factor Ab
Recombinant human tissue pathway (+)
Ibuprofen
N-acetylcysteine
Nitric Oxide Inhibitors
Growth Hormone
Bradykinin Antagonists
Levosimendan
Hypothermia
Hyperoxia
Hypertonic saline
Hemoperfusion through Polymyxin B
Interleukin 1 Receptor Antagonist
TLR-4 Antagonist
Anti-Endotoxin Antibody
Activated Protein C
Recombinant Thrombomodulin

Why Heterogeneity Matters





Heterogeneity of Treatment Effect

Summary So Far...

Common and Highly Morbid Conditions


+ Importance of Early Recognition and Intervention

+ Heterogeneous Groups


+ Need for More Targeted Trials and Therapies

= *Opportunity for Network Physiology??*


Critical Illness and Network Physiology: Multi-organ Failure



- Sepsis is defined by dysfunction of multiple organs and is a systems disease
- ARDS (although a “pulmonary” disease) is often part of a cycle of inflammation and organ failure



Critical Illness and Network Physiology: The Data




- The ICU is a data rich environment...
- Standard of care* is continuous monitoring of multiple organ systems
- Electronic medical record and central storage of monitoring data

* In well resourced settings



Critical Care and Network Physiology



47 year old healthy man presents with subjective fever, muscle aches and vague abdominal pain.

Evaluated in ED, sent home with wearable device

Called back into ED for early re-evaluation based on data profile

Identified as Sepsis Endotype X and started on antibiotics and a specific, newly identified drug

Patient feels better, blood cultures grow GPCs and antibiotics are narrowed appropriately

Blood cultures cleared, patient discharged home

Day 1

Day 3
01:00

Day 3
08:00

Day 3
23:00

Day 6
010:00



kahibbert@mgh.harvard.edu